NCT01018251

Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer

Monitoring Treatment Response in Women With Breast Cancer Utilizing FLT-PET/CT

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the sensitivity and specificity of FLT-PET/CT in primary breast cancer detection and in the use of FLT-PET in monitoring how well a breast tumor respond to treatment. We will compare this technique with other imaging modalities as well as with tissue collection (during a biopsy). We will recruit women with a newly diagnosed invasive breast cancer, who are able to tolerate undergoing a PET/CT (possibly two scans) scan,

Detailed description

Our overall goal is to use this clinical trial as a platform to validate fibroblast activation protein (FAP) as a biomarker for the tumor microenvironment and to explore the dynamic interaction between proliferating tumor cells and the tumor microenvironment. Our long term goal is to develop new drugs that will target the tumor microenvironment as novel therapeutic and chemoprevention strategies.

Conditions

• Adult Women With a New Diagnosis of Invasive Breast Cancer (Have Not Undergone Treatment)

Interventions

Type	Name	Description
OTHER	3'-deoxy-3'-[18F]fluorothymidine	Given IV
PROCEDURE	Positron Emission Tomography/computed tomography
RADIATION	FLT-PET/CT

Timeline

• Start date: 2009-03-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2009-11-23
• Last updated: 2015-12-15